Phase 2
N=392
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
Influenza
Bottom Line
View on ClinicalTrials.gov: NCT01147068 ↗Enrolled (actual)
392
Serious AEs
2.6%
Results posted
Nov 2012
Primary outcome: Primary: Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age. — 0; 32; 15; 82 percentage of participants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- 0.5mL Intramuscular Injection (Biological)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Protein Sciences Corporation
- Primary completion
- Oct 2011
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Evaluation of Immunogenicity Measured by Seroconversion Rates of PanBlok With and Without Adjuvant Compared to Placebo in Healthy Adults 18-49 Years of Age. |
0; 32; 15; 82; 75; 66 | — |
| SECONDARY Evaluation and Comparison of Immunogenicity From Geometric Mean Titers of PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age. |
NA; NA; NA; NA; NA; NA | — |
| SECONDARY Serologic Response Rates at Day 21 Using PanBlok With and Without Adjuvant and Placebo in Healthy Adults 18-64 Years of Age |
3; 4; 4; 11; 7; 8 | — |
Summary
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA formulations and 2 dose levels in unadjuvanted rHA formulations.
Eligibility Criteria
Inclusion Criteria
- Male or female aged 18-49 years.
- Give written informed consent to participate.
- Healthy, as determined by medical history, physical examination, vital signs, and clinical safety laboratory evaluation
- Females should fulfill one of the following criteria:
- At least one year post-menopausal;
- Surgically sterile;
- Will use oral, implantable, transdermal or injectable contraceptives for 30 days prior to first vaccination and until 28 days after the booster vaccination; or
- Willing to use another reliable form of contraception approved by the Investigator (e.g., intrauterine device (IUD), female condom, diaphragm with spermicide, cervical cap, use of condom by the sexual partner or a sterile sexual partner) for 30 days prior to first vaccination and until 28 days after the booster vaccination.
- Women of childbearing potential must have a negative urine pregnancy test within 24 hours preceding receipt of first and booster vaccinations
- Comprehension of the study requirements, expressed availability for the required study period, and ability to attend scheduled visits.
Exclusion Criteria
- Persons under 18 years old or 50 years or older
- Persons with chronic illnesses such as cancer, diabetes, liver or kidney disease
- Persons taking medications or treatments that may adversely affect the immune system
- Persons with known allergy to eggs or other vaccine or adjuvant components
- Person currently pregnant, nursing mothers or planning a pregnancy within one month of vaccination
- Persons who have had a prior serious reaction to any influenza vaccine
- Persons with a known history of Guillain-Barré Syndrome
- Persons with a history of anaphylactic-type reaction to injected vaccines
- Persons with a history of drug or chemical abuse in the year preceding the study
- Persons who previously received an H5N1 influenza vaccine or who plan to receive an H5N1 influenza vaccine while participating in the study
- Persons who received a seasonal influenza vaccine six months prior to enrollment (may delay enrollment)
- Persons who received any other vaccine within one week prior to enrollment (may delay enrollment)
- Persons who have had a respiratory illness or illness with fever within three days of study enrollment (may delay enrollment)
- Persons currently participating in another research study involving any study medications (investigational drugs or vaccines).
Data sourced from ClinicalTrials.gov (NCT01147068). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.